KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer

KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer

Abstract Immunotherapy had shown good antitumor activity in a variety of solid tumors, but low benefit in CRC, so there was an urgent need to explore new biomarkers. We evaluated the role of KMT2C using publicly available data from the Cancer Genome Atlas (TCGA) and Memorial Sloan Kettering Cancer C...

Full description

Bibliographic Details
Main Authors: Chunhua Ni, Xiaohong Wang, Shaoping Liu, Junling Zhang, Zhongguang Luo, Bei Xu
Format: Article
Language:English
Published: Nature Portfolio 2024-04-01
Series:Scientific Reports
Subjects:
Colorectal cancer
Immunotherapy
Tumor mutational burden
Microsatellite instable
Immune cell infiltration
Online Access:https://doi.org/10.1038/s41598-024-57519-8

Internet

https://doi.org/10.1038/s41598-024-57519-8

Similar Items